The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and interchangeable products. Subsequent releases will expand the database to include all FDA-approved biological products, currently available only in a table format

Related News Articles

Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation,…
Headline
The Campaign for Sustainable Rx Pricing (CSRxP), of which the AHA is a founding member, today launched new television and digital advertising encouraging…